Skip to main content
OpenTrials
Completed

NCT Number: NCT05692752

Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction

Cardiac-enriched micro-RNAs (miRNAs), micro RNA 208b and 133a(MiR-208b, MiR-133a)) corresponds to the health and disorders of the cardiovascular system. An intron of the cardiac myosin heavy chain gene MYH7 encodes miR-208b. It is found on chromosome 14 in humans. Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cardiac troponine (cTnl) and Creatine kinase-MB (CK-MB).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myocardial Infarction, Acute Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Infarction Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

35 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance Al Tagamoa Al Khames

Cairo, 11835, Egypt

About this study

The 98% of human genes are non-coding RNA, which is further divided into long non-coding RNA (lncRNA, > 200 bp) and short non-coding RNA (200 bp, including microRNA (miRNA) and circular RNA). More than 2000 human miRNAs have been discovered, and it seems that they regulate around 60% of human genes.Through a number of pathways, miRNAs control the development, re-modelling, and regeneration of the heart as well as endothelial function, vasculo-genesis, and neoangiogenesis. 30% of the genes in the human genome are regulated by about 1000 miRNAs. Endogenous miRNAs are 19-22 nucleotide single-stranded RNA molecules that frequently target the 3' untranslated regions (3'-UTR) of mRNAs to regulate gene expression at the post-transcriptional level in physiological processes, disease development, and conditions like cancer, autoimmune and inflammatory diseases, neuro-degenerative diseases, and cardiovascular diseases. Cardiac-enriched miRNAs, MiR-208 in health and disorders of the cardiovascular system are investigated.

Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cTnl and CK-MB.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with ST-Elevated Myocardial Infarction will be identified at the Coronary Care Unit at Ain-shams University hospital
  • Acute episode of Myocardial Infarction
  • With No history of previous Myocardial Infarction Treatment

Exclusion criteria

  • Patients not diagnosed with ST-Elevated Myocardial Infarction and healthy at the Coronary Care Unit at Ain-shams 2. University hospital
  • Previously Known patients of Myocardial infacrtion
  • Previous medication

Treatment and study plan

No intervention

Other

Expression of miR-133a &208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms

Other names: Expression of miR-133a & 208b

Primary outcomes

  1. Expression of miR-133a

    Time frame: 04 hours from the onset of the infarct

    Expression during episodes of myocardial infarction

  2. Expression of miR-133a

    Time frame: 08 hours from the onset of the infarct

    Expression during episodes of myocardial infarction

  3. Expression of miR-133a

    Time frame: 12 hours from the onset of the infarct

    Expression during episodes of myocardial infarction

  4. Expression of miR-133a

    Time frame: 24 hours from the onset of the infarct

    Expression during episodes of myocardial infarction

  5. Expression of miR-133a

    Time frame: 48 hours from the onset of the infarct

    Expression during episodes of myocardial infarction

  6. Expression of miR-208b

    Time frame: 04 hours from the onset of the infarct

    Expression during episodes of myocardial infarction

  7. Expression of miR-208b

    Time frame: 08 hours from the onset of the infarct

    Expression during episodes of myocardial infarction

  8. Expression of miR-208b

    Time frame: 12 hours from the onset of the infarct

    Expression during episodes of myocardial infarction

  9. Expression of miR-208b

    Time frame: 24 hours from the onset of the infarct

    Expression during episodes of myocardial infarction

  10. Expression of miR-208b

    Time frame: 48 hours from the onset of the infarct

    Expression during episodes of myocardial infarction

Sponsors and collaborators

Lead sponsor

Islamia University of Bahawalpur

Other

Collaborators

  • German University in Cairo

Registry information

Official study title

Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction Egyptian Patients

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jan 20, 2023
Registry last updated
Jan 20, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.